In a study exploring the effects of combination therapy with benznidazole and posaconazole in T. cruzi carriers, authors observed no advantages with combined therapy when compared to benznidazole monotherapy. The study, published in the Journal of the American College of Cardiology, reports that among individuals with chronic asymptomatic T. cruzi infection, posaconazole had significant short-term trypanostatic therapy; however, this effect was not sustained. Monotherapy with benznidazole was superior to posaconazole monotherapy, and achieved conversion of T. cruzi in all subjects on treatment by 30 days, which was sustained for at least one year. Read more >>>